Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.

Paul W Jones; Rosa Lamarca; Ferran Chuecos; Dave Singh; Alvar Agustí; Eric D Bateman; Gonzalo de Miquel; Cynthia Caracta; Esther Garcia Gil

doi:10.1183/09031936.00038814

Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.

Paul W Jones, Rosa Lamarca, Ferran Chuecos, Dave Singh, Alvar Agustí, Eric D Bateman, Gonzalo de Miquel, Cynthia Caracta, Esther Garcia Gil

Research output: Contribution to journal › Article › peer-review

Abstract

The frequency and impact of exacerbations identified using healthcare resource utilisation (HCRU) or the EXAcerbations of Chronic pulmonary disease Tool (EXACT) were compared prospectively in a 24-week, phase III trial (ATTAIN). Patients with moderate-to-severe chronic obstructive pulmonary disease received twice-daily aclidinium 200 μg, aclidinium 400 μg or placebo. All HCRU events were reported to physicians. "EXACT-identified" events were categorised as "EXACT-reported" (detected by EXACT and reported to the physician) and "EXACT-unreported" (detected but not reported). Health status was measured using the St George's Respiratory Questionnaire (SGRQ). Annualised EXACT-identified event rates were higher in all study arms (placebo 1.39, aclidinium 200 μg 1.00 and aclidinium 400 μg 0.98 per patient per year) versus HCRU (placebo 0.60, aclidinium 200 μg 0.43 and aclidinium 400 μg 0.40 per patient per year). Concordance between methods was low (kappa 0.16). Aclidinium reduced EXACT-identified events (rate ratio versus placebo: aclidinium 200 μg 0.72 and aclidinium 400 μg 0.71; both p

Original language	English
Journal	The European respiratory journal
DOIs	https://doi.org/10.1183/09031936.00038814
Publication status	Published - 18 Sept 2014

Access to Document

10.1183/09031936.00038814

Cite this

@article{5401387ad0084d56b10e1420c7fcd545,

title = "Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.",

abstract = "The frequency and impact of exacerbations identified using healthcare resource utilisation (HCRU) or the EXAcerbations of Chronic pulmonary disease Tool (EXACT) were compared prospectively in a 24-week, phase III trial (ATTAIN). Patients with moderate-to-severe chronic obstructive pulmonary disease received twice-daily aclidinium 200 μg, aclidinium 400 μg or placebo. All HCRU events were reported to physicians. {"}EXACT-identified{"} events were categorised as {"}EXACT-reported{"} (detected by EXACT and reported to the physician) and {"}EXACT-unreported{"} (detected but not reported). Health status was measured using the St George's Respiratory Questionnaire (SGRQ). Annualised EXACT-identified event rates were higher in all study arms (placebo 1.39, aclidinium 200 μg 1.00 and aclidinium 400 μg 0.98 per patient per year) versus HCRU (placebo 0.60, aclidinium 200 μg 0.43 and aclidinium 400 μg 0.40 per patient per year). Concordance between methods was low (kappa 0.16). Aclidinium reduced EXACT-identified events (rate ratio versus placebo: aclidinium 200 μg 0.72 and aclidinium 400 μg 0.71; both p",

author = "Jones, {Paul W} and Rosa Lamarca and Ferran Chuecos and Dave Singh and Alvar Agust{\'i} and Bateman, {Eric D} and {de Miquel}, Gonzalo and Cynthia Caracta and {Garcia Gil}, Esther",

year = "2014",

month = sep,

day = "18",

doi = "10.1183/09031936.00038814",

language = "English",

journal = "The European respiratory journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

}

TY - JOUR

T1 - Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.

AU - Jones, Paul W

AU - Lamarca, Rosa

AU - Chuecos, Ferran

AU - Singh, Dave

AU - Agustí, Alvar

AU - Bateman, Eric D

AU - de Miquel, Gonzalo

AU - Caracta, Cynthia

AU - Garcia Gil, Esther

PY - 2014/9/18

Y1 - 2014/9/18

N2 - The frequency and impact of exacerbations identified using healthcare resource utilisation (HCRU) or the EXAcerbations of Chronic pulmonary disease Tool (EXACT) were compared prospectively in a 24-week, phase III trial (ATTAIN). Patients with moderate-to-severe chronic obstructive pulmonary disease received twice-daily aclidinium 200 μg, aclidinium 400 μg or placebo. All HCRU events were reported to physicians. "EXACT-identified" events were categorised as "EXACT-reported" (detected by EXACT and reported to the physician) and "EXACT-unreported" (detected but not reported). Health status was measured using the St George's Respiratory Questionnaire (SGRQ). Annualised EXACT-identified event rates were higher in all study arms (placebo 1.39, aclidinium 200 μg 1.00 and aclidinium 400 μg 0.98 per patient per year) versus HCRU (placebo 0.60, aclidinium 200 μg 0.43 and aclidinium 400 μg 0.40 per patient per year). Concordance between methods was low (kappa 0.16). Aclidinium reduced EXACT-identified events (rate ratio versus placebo: aclidinium 200 μg 0.72 and aclidinium 400 μg 0.71; both p

AB - The frequency and impact of exacerbations identified using healthcare resource utilisation (HCRU) or the EXAcerbations of Chronic pulmonary disease Tool (EXACT) were compared prospectively in a 24-week, phase III trial (ATTAIN). Patients with moderate-to-severe chronic obstructive pulmonary disease received twice-daily aclidinium 200 μg, aclidinium 400 μg or placebo. All HCRU events were reported to physicians. "EXACT-identified" events were categorised as "EXACT-reported" (detected by EXACT and reported to the physician) and "EXACT-unreported" (detected but not reported). Health status was measured using the St George's Respiratory Questionnaire (SGRQ). Annualised EXACT-identified event rates were higher in all study arms (placebo 1.39, aclidinium 200 μg 1.00 and aclidinium 400 μg 0.98 per patient per year) versus HCRU (placebo 0.60, aclidinium 200 μg 0.43 and aclidinium 400 μg 0.40 per patient per year). Concordance between methods was low (kappa 0.16). Aclidinium reduced EXACT-identified events (rate ratio versus placebo: aclidinium 200 μg 0.72 and aclidinium 400 μg 0.71; both p

U2 - 10.1183/09031936.00038814

DO - 10.1183/09031936.00038814

M3 - Article

C2 - 25234803

SN - 0903-1936

JO - The European respiratory journal

JF - The European respiratory journal

ER -

Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.

Abstract

Access to Document

Fingerprint

Cite this